FVB-Il31raem2Phep/Cnrm
Status | Available to order |
EMMA ID | EM:11961 |
International strain name | FVB-Il31raem2Phep/Cnrm |
Alternative name | Il31raS476F |
Strain type | Endonuclease-mediated |
Allele/Transgene symbol | Il31raem2Phep, |
Gene/Transgene symbol | Il31ra |
Information from provider
Provider | Paul Heppenstall |
Provider affiliation | European Molecular Biology Laboratory |
Genetic information | This mouse strain was generated using CRISPR/Cas9-mediated genome editing to knock-in a point mutation within exon 14 of the locus Il31ra (TCT>TTT) resulting in an aminoacid substitution in position 476 of a serine with a phenylalanine. |
Phenotypic information | Homozygous:Homozygous mice show spontaneous fur loss, sometimes with severe skin lesions all over the body, amyloid deposits in the skin (detectable with specific staining) and itchy skin.Heterozygous:Heterozygous mice show spontaneous fur loss, sometimes with severe skin lesions all over the body, amyloid deposits in the skin (detectable with specific staining) and itchy skin. |
References |
|
Homozygous fertile | yes |
Homozygous viable | yes |
Homozygous matings required | not known |
Immunocompromised | no |
Information from EMMA
Archiving centre | CNR, Consiglio Nazionale delle Ricerche, Monterotondo, Italy |
Disease and phenotype information
Orphanet associated rare diseases, based on orthologous gene matching
- Familial primary localized cutaneous amyloidosis / Orphanet_353220
Literature references
- Interleukin-31-mediated photoablation of pruritogenic epidermal neurons reduces itch-associated behaviours in mice.;Nocchi Linda, Roy Nainika, D'Attilia Mariangela, Dhandapani Rahul, Maffei Mariano, Traista Andrei, Castaldi Laura, Perlas Emerald, Chadick Cora Hallie, Heppenstall Paul A, ;2019;Nature biomedical engineering;3;114-125; 30944432
Information on how we integrate external resources can be found here
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).